Medical practitioners typically utilize the following protocol when advising pregnant women about testing for the possibility of genetic disorders: Pregnant women over the age of 35 should be tested for Down syndrome and other genetic disorders; for younger women, such tests are discouraged since they can cause a miscarriage. The logic appears compelling. The rate at which amniocentesis causes a miscarriage is constant while genetic disorders rise over a woman's reproductive years. Hence the potential benefit from testing -being able to terminate a fetus with a genetic disorder -rises with maternal age. We argue that this logic is incomplete. While the benefits to testing rise with age, so do the costs. While undergoing an amniocentesis always entails the risk of miscarriage of a healthy fetus, these costs are lower at early ages, because there is a higher probability of being able to replace a miscarried fetus with a healthy birth at a later age. We develop and calibrate a dynamic model of amniocentesis choice to explore this tradeoff. For parameters that characterize realistic age patterns of chromosomal abnormalities, fertility rates and miscarriages following amniocentesis, our model implies a falling, rather than rising, rate of amniocentesis as women approach menopause.
Introduction

Amniocentesis and chorionic villus sampling (CVS) are methods of diagnosing Downs
Syndrome and other genetic disorders. Amniocentesis and transabdominal CVS involve inserting a thin hollow needle through a pregnant woman's abdomen to remove fetal cells from the amniotic sac (amniocentesis) or from around the chorionic villi (CVS). Children with Down syndrome suffer from general hypotonia (poor muscle strength and elasticity), mental retardation, growth retardation, and are at significant risk for congenital malformations of which heart problems are the most common. While some therapies are available for specific malformations there are no proven therapies available to treat the cognitive problems associated with Down syndrome (Dick, et al., 1996) . In developing countries, life expectancy for children with Down syndrome is approximately 35 years (Brazil) but advances in medical treatment for specific conditions has increased life-expectancy in the U.S. to approximately 55 years. 2 The lifetime economic cost of Down syndrome is estimated at $410,000 per child based on U.S. cross-sectional data from 1988 (Waitzman, Romano & Scheffler, 1994) . This of course greatly underestimates the full cost to families which include maternal depression and difficulties with marital and sibling relationships (Dick, et al., 1996) . Down syndrome accounts for about half of chromosomal abnormalities detected by karyotyping.
Spina bifida (an incompletely enclosed spinal cord) and anencephaly (the absence of a large part of the brain and skull) are two less common but more fatal genetic disorders detected by amniocentesis and CVS.
Both CVS and amniocentesis provide very accurate diagnosis of Down syndrome in a fetus, greater than 99%. However, both have important risks that a pregnant woman must consider. The amniocentesis procedure results in a spontaneous miscarriage for 1 in 100 to 1 in 200 women and the CVS procedure carries an even greater risk of procedure-related fetal loss (between 1% and 1.5%).
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And while the fraction of pregnancies afflicted with Down syndrome and other genetic disorders rises with maternal age, even at age 49 the vast majority of pregnancies will prove to be chromosomally normal. What this means is that when amniocentesis induces the loss of a fetus, the mother almost always looses a fetus that would have developed into a healthy child.
The current standard in obstetric practice is to recommend that women pregnant at age 35 or older have an amniocentesis or CVS but this is not recommended for pregnant women prior to that age. The American College of Obstetricians and Gynecologists, the College of Medical Genetics and the Canadian Task Force on Periodic Health Examination all agree that a woman who is pregnant and is 35 years old or older should be tested using either amniocentesis or CVS.
The recommendations for women who are pregnant and younger than age 35 varies, but generally either the "triple marker" test or no test at all is recommended. 4 Using age 35 as an age 3 See U.S. Preventative Service Task Force. (1996) . The CVS procedure is feasible to perform earlier in a pregnancy than is amniocentesis. to start testing is based on a compelling, but we argue, incomplete logic. Figure 1 graphs the estimated number of fetuses afflicted with a chromosomal abnormality per 100,000 pregnancies by maternal age. Figure 1 also displays an upper and lower bound estimate on the number of fetuses lost for every 100,000 amniocenteses performed. It is clear that prior to ages 35-38 more healthy fetuses would be lost from performing amniocentesis on all women than would be the number of chromosomally abnormal fetuses detected. It is further argued that, after age 35-38, when chromosomal abnormalities rise rapidly, the rate of successful detection of rate chromosomal abnormal fetuses via amniocenteses exceeds the incidence of miscarriages resulting from administering this procedure. It is the latter claim (and accompanying evidence) that has led the medical profession to adopt age 35 as the threshold age for recommending genetic testing to patients.
Figure 1 here
Economists have criticized this threshold-age approach. For example, Sicherman, Bombard and Rappoport (1995) (SBR hereafter) point out that this approach makes sense from an expected utility theory viewpoint only if the utility loss from a miscarriage due to having an amniocentesis equals the utility gain from avoiding bearing and raising a Down syndrome child.
Clearly, women (parents) may differ with respect to how they value the "pain and loss" associated with miscarrying a fetus, on terminating a pregnancy through abortion, and on how they value having additional children, including the relative utility gained from a healthy child versus one born with a chromosomal abnormality. SBR argue that a woman's individual costs and benefits of each outcome can be combined with the probabilities of those outcomes to better aid women in their choice.
60% of Down syndrome fetuses. Some doctors will perform amniocentesis on women who test positive on the "triple marker" test. Because of the extremely high false positive rate others will not use the test at all. Like SBR, this paper relies on an expected utility approach but differs from SBR in an important way. While SBR set the expected utility model in a static context, our paper concentrates on the dynamic decisions inherent in family planning. Specifically, we model a woman's choice about amniocentesis for a particular pregnancy within her lifetime choices over the quantity and quality of children.
There is a long tradition in demography that recognizes the importance of the outcomes for one child or one pregnancy on future choices about childbearing. For example, demographers have extensively studied changes in fertility in response to infant mortality, especially in developing countries (Shultz, 1969 (Shultz, , 1976 Ben-Porath, 1976; Preston, 1978; Sah, 1991; Wolpin, 1997 ). In our model, a procedure-induced miscarriage is viewed as in utero "infant mortality" but women can partially control this risk by their decisions of whether or not to have an amniocentesis. In particular, by not undergoing an amniocentesis, a woman can limit the risk of this form of infant mortality. At the same time, by not having an amniocentesis, she increases her chances of bearing a child with Down syndrome or another genetic disorder. In making her genetic-testing choice, a woman is always cognizant that she can replace a miscarried fetus, with some probability, at later ages. However, this option decreases as a woman approaches menopause. As a result, the "cost" of an amniocentesis rises with maternal age. This is the key different between our model and static expected utility models. In particular, the static model of SBR implies that women will always have a rising propensity to choose to undergo an amniocentesis because of her desire to avoid having a child born with a genetic disorder. In our dynamic model, this propensity may or may not rise with maternal age, precisely because women must balance the benefits associated with having an amniocentesis (avoiding having a child with a genetic disorder) with the costs of such procedures (running the risk of a procedure-induced miscarriage of a healthy fetus).
The remainder of this article is organized as follows. Section 2 lays out a dynamic model of amniocentesis. We show that if the rate of Down syndrome were constant over maternal age, it would be optimal, in the sense of maximizing expected utility, for women to elect an amniocentesis at younger ages rather than at older ages. Since genetic disorders do rise with maternal age, this result makes clear that how the optimal choice changes with maternal age will depend on the rate of increase in genetic disorders relative to the rate of decrease in the probability of replacing a child lost by a procedure-induced amniocentesis. After laying out how the rates of amniocentesis vary by age and birth parity in U.S. data in Section 3, we then solve more realistic models, using numerical methods and plausible parameter values, to determine what the age pattern of amniocentesis choice might look like under reasonable biological parameters. The results of these simulations are presented in Section 4. Some implications of our simple model are strongly rejected by the data. For example, the data shows a clear jump in amniocentesis rates at age 35, the age threshold used by medical practitioners. However, other implications of the model are consistent with the data in Section 3, including: (a) a decline in amniocentesis rates as women approach the end of their reproductive years, (b) a higher rate of amniocentesis for lower parity children at most maternal ages, and (c) a larger drop in amniocentesis rates for lower parity children as a woman reaches menopause. Section 5 provides concluding observations.
Modeling Amniocentesis Choice
The Elements of a Dynamic Model
Consider a model in which women, at each age t, t = 1,…,T, become pregnant. We treat pregnancies as biologically (and exogenously) determined, occurring with probability p t , 0 < p t < 1. Age T+1 is the age of menopause, after which woman's probability of conception is zero (i.e., 
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Amnio, may experience a (spontaneous) miscarriage, with probability m, 0 < m < 1. If the mother chooses not to undergo an amniocentesis, the pregnancy will end in a normal birth with probability q and a birth with a genetic disorder with probability (1-q). If she undergoes the procedure, the result of the test will be negative (no genetic abnormalities) or positive with the same probabilities (q and 1-q). The probability of a genetic disorder, (1-q), varies with the woman's age.
The above set of actions and probabilistically-occurring events result in a set of potential outcomes at each age. In particular, women may have: a normal birth at age t, denoted by n t = 1; a birth with a genetic disorder (Down syndrome), denoted by d t = 1; a miscarriage, denoted by m t = 1; an abortion, denoted by a t = 1; or no pregnancy, which is (implicitly) recorded by n t = d t = m t = a t = 0. Let the cumulative values, or "stocks," of these outcomes as of age t be denoted as X t = X t-1 + x t , where X = N, D, M, and A correspond to the outcomes x = n, d, m, and a.
An essential feature of our model is that children, regardless of their type, are enduring goods. Furthermore, a couple's other choices may have long run consequences. As such, we assume that parent's instantaneous utility, u t , is a function of the accumulated choices and outcomes. Furthermore, couples will differ on the utility value of each of these. For example, some couples may get as much utility from a Down child as a healthy child, and other couples (women) may face a large utility cost of abortion while other women face none. These differences in tastes are known to a couple but are unknown to the econometrician. We model the instantaneous utility function as the sum of the utilities derived over the accumulation of each pregnancy event. That is,
where t=T, we assume that a woman will enjoy the utility from a child forever. 6 We assume a couple (woman) will make their (her) decisions between t=1 and t=T, looking to maximize their (her) expected lifetime utility function: 
and the choice and outcome probabilities are given by
where the operator, 1{x}, is equal to one if decision x is taken and 0 otherwise. (The structure of the woman's decision problem at age t is illustrated as a decision tree in Figure 2 .) Notice that the probabilities are age dependent because some of the parameters, like the probability of having a child with Down syndrome (q t ), are age dependent. We assume that 
the child is born with Down syndrome. As the woman desires only one child, we can assume that after the birth of her child a woman receives her discounted utility payoff and then dies. If she does not have a child by age T (the age of menopause), her utility is zero. Finally, for now, we assume that m, q, and p do not vary with maternal age. While many of these simplifying assumptions are either unrealistic or factually inaccurate, they allow us to simplify a woman's fertility decision-making problem. For example, it follows immediately from the above assumptions that in our simplified model we can abstract from the choice of whether to abort a pregnancy prior to genetic testing (
We consider the two remaining choices and describe how this simplified model can be solved recursively.
Last Stage, Age T Consider the last stage of the woman's decision problem, at age T, after which she can no longer become pregnant. Figure 3 displays the decision tree for this age. We first consider the abortion decision, given a positive outcome on an amniocentesis (
) and then determine her optimal amniocentesis decision rule.
Figure 3 here
If a woman has had an amniocentesis, avoided a procedure-induced miscarriage and then tested positive for Down syndrome, the woman will abort the pregnancy if the value of a Down syndrome child is negative, since the only issue is whether a child afflicted with Down syndrome will produce positive utility to the woman. Thus, it follows that the optimal abortion choice at age T is characterized by the following decision rule:
Given a value of 1 D  , a woman will know whether she will abort should she be faced with a fetus with a genetic disorder and can make a choice at age T on whether to undergo amniocentesis. If 1 D   0, we know that the woman will not abort. We also know she will not undergo an amniocentesis; doing so generates no present benefits (she will not abort if she tests positive) and entails the risk of miscarriage. In contrast, a woman with 1 D  < 0 would abort a 7 Since the choice to abort after genetic testing is available, and since abortion carries no disutility, a woman will never abort prior to genetic testing if
fetus if it tested positive for Down syndrome. It follows that the woman's her expected utility is
if she undergoes an amniocentesis and
otherwise. Equating (8) and (9) and solving for  yields
which is that level of utility, as of age T, at which a woman is indifferent between having an amniocentesis and aborting if it tests positive and not having an amniocentesis. Thus, * T  is the critical (utility) value that characterizes the optimal decision rule for a woman's amniocentesis choice at age T:
Note that it is possible that some women will decide to forgo an amniocentesis, even though having a Down syndrome child would reduce their utility, i.e., 1 D  < 0. This could occur because while having an amniocentesis allow a woman to avoid having a Down syndrome child with certainty, having the test comes with the risk of losing a healthy child due to a miscarriage.
Before moving to age T-1, notice that the choice over amniocentesis only occurs among women pregnant at T. Therefore, as of age T-1, the payoffs at age T are expected to be Choices at Age T-1 Figure 4 displays the decision tree for a woman at her next-to-last fertile age, T-1. At this age, women still have choices they can make when they reach age T and these potential actions have option value as of age T-1. Recall that at age T any woman with otherwise.
Since a woman would undergo amniocentesis only if she would abort a fetus that tests positive for a chromosomal abnormality, it follows immediately that
this range, it follows from (11) that a woman would not have amniocentesis at age T should she reach age T without a child and become pregnant at age T. Therefore, 8 Note that with more than one child, the (utility) costs of an amniocentesis will not be constant.
which implies that
and the optimal amniocentesis decision-rule at age T-1 is:
Given that the choice of amniocentesis occurs only among women pregnant at age T-1, it follows that the expected future utility as of age T-2 is given by one of the following three expressions, (1 )
(1 )
(1 ) 
otherwise.
or, at an arbitrary age, T-s, by:
, otherwise.
Since a woman would undergo amniocentesis only when she would abort a fetus that tests positive for a chromosomal abnormality, this immediately implies that
And, thus,
range, a woman would not have amniocentesis at any (fertile) age after T-s. Therefore,
Thus, the critical value for 1 D  for an arbitrary age T-s is given by to "fit the data," we present, in the following section, evidence on the empirical relationship between amniocentesis and age.
Empirical Regularities on Amniocentesis and Maternal Age
To investigate the relationship between age and amniocentesis, we use data from the Detailed Natality Files (DNF) from the National Center for Health Statistics. The DNF include all births occurring within the United States. Beginning in 1988, for nearly every state, both congenital anomalies and a woman's use of amniocenteses during pregnancy are recorded.
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While some twenty-two congenital anomalies are recorded, many are not genetic in origin.
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In what follows, we concentrate on the data for three anomalies that are routinely discovered by amniocentesis: spina bifida, Down's syndrome, and "other chromosomal anomalies." These anomalies comprise more than half of all genetic disorders associated with newborns.
The benefit of the DNF is that it is a census of births in the U.S. and provides sufficient sample size to study choices of women pregnant at older ages. One potential issue is that this is a sample of live births only and hence Down's syndrome fetuses that are aborted do not appear in the sample. However, it is possible to estimate the fraction of pregnancies for which amniocentesis is performed from the sample of live births.
From the DNF, we can obtain the following statistics:
Birth rt N = Total number of births of parity r occurring to women of age t; 
where b rt = 1 indicates a live birth of birth order r to a woman of age t.
For our purposes, we are interested in the rate of amniocentesis conditional on pregnancies and only on "relevant" pregnancies. In particular, an amniocentesis is not a relevant choice for a woman who would elect to abort a pregnancy, without regard to its genetic status, or for a woman who has a naturally occurring miscarriage prior to the amniocentesis choice. 
where ( 
where Amnio rt is the indicator on whether a woman had an amniocentesis at age t for parity r and 
, and e indexes education groups. First, regardless of parity, the rate of amniocentesis is near zero for women under the age of 35, but there is a steep rise in the rate of amniocentesis after that age for all parities. Second, the increase in rate of amniocentesis is larger the lower the parity of the child. Finally, while amniocentesis rates rise until a woman reach her mid-forties, they begin to decline after that age and they drop more precipitously for lower parities (first through third) than higher (fourth) parities. In particular, between the ages of 46 to 48, the rate of amniocentesis drops from 31% to 20% for first births, from 28% to 14% for second births, and from 45% to 23% for third births. In contrast, there is very little decline in the corresponding rates for fourth births over this same age range.
Figure 5 here
These age and parity patterns in rates of amniocentesis may be the result of changes in the composition of women across these groups. As noted above, women having a first birth at age 20 are likely to be less educated than those having their first birth at age 40. One easy way to account for this compositional effect on these rates is to condition, non-parametrically, on the educational attainment of women. and for first through fourth parities for women whose highest level of educational attainment was a high school diploma. What is clear is that the patterns described for all women persist although the differences in the rates at any age across parity are reduced. Amnio p  when the distribution of race, marriage and education is held constant for all parities and for all ages at the distribution found for women having a second birth at age 35.
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13 Blacks, Hispanic, Others and Whites make up 11.0%, 11.6%, 6.0% and 72.4% of this population respectively. High School dropouts, high school graduates, some college and college graduates make up 14.4%, 26.6%, 22.7%, Again, for the first through third children, the patterns remain.  Almost no women undergo an amniocentesis prior to age 35.
 The rate at which women undergo the procedure rises rapidly after age 35, rising more the lower the child parity.
 At every parity, the rate of amniocentesis declines as a woman approaches the end of her reproductive years.
Presumably, the first and second of these patterns are heavily influenced by the "rules" that health care providers and insurance companies follow with respect to what ages they advise women to have an amniocentesis and the age-related restrictions that health care providers and insurers place on the reimbursements of this procedure that were noted in the Introduction. But it is less clear how to account for the third pattern, namely, that the incidence of amniocenteses by birth parity decline towards the end of woman's reproductive lives.
As we already have seen, a simple version of a life cycle model of optimal amniocentesis choice appears to be inconsistent with the first two of the above life cycle patterns observed in the data for amniocenteses, although it does tend to characterize the third one. In the following section, we consider the life cycle patterns that are generated by more complicated versions of our dynamic model, examining how the model's predictions concerning life cycle variation in the likelihood of having an amniocentesis change as we vary the rate of discounting, the utility costs of abortions and miscarriages and with age-variation in the rates of genetic disorders, such and 40.3% respectively of this population respectively. 85.6% of this population is married. Figure 7 is constructed through regression adjustments and then equation (25) is applied. In future versions of this paper these will be constructed entirely non-parametrically.
as displayed in Figure 1 . We contrast these predictions with those generated by a myopic model of amniocentesis choice, exploiting the fact that such a model arises as a special case of our dynamic model under the case where the future is completely discounted (i.e.,  = 0.0) when women (couples) make their childbearing and amniocentesis decisions.
Varying Features of the Model and Tracking the Observed Dynamic Patterns of Amniocentesis Choice
In this section, we examine how changes in the various features of our dynamic model of amniocentesis choice affect our ability to "replicate" the age patterns found in the data on the incidence of amniocenteses described in the preceding section. We pay particular attention to contrasting our dynamic model with the special case in which women are myopic with respect to these choices, i.e., do not take full account of the future in making their choices. In this exploration, our goal is not to fit our model to data in a statistical sense. Rather, our goal is to see whether our model, and its underlying features, is rich enough to characterize the dynamic patterns of amniocentesis choice outlined above. We proceed by plugging in values for the key parameters (or rates) for the model in Section 2 in an attempt to "calibrate" the model, assessing how well we mimic the dynamic patterns of amniocentesis choice at different ages by plotting how the critical value, * t  , for 1 D  varies with age.
14 To simplify our analysis, we normalize the value of a (chromosomally) healthy child to one ( 1 N  = 1), and specify the following parameters of the model to be age-invariant and equal to the following values: annual pregnancy rate (p) to 0.3 and the rate of procedure-induced miscarriage (m) to 0.0067 (1/150). We then explore how varying the following parameters affects * t  and thus the incidence of amniocenteses with age:
14 That is, the incidence of amniocenteses at a woman's age, t, is given by (i) the discount rate (); (ii) the utility cost of an abortion (); (iii) the utility cost of a miscarriage (); and (iv) the rate of genetic disorders (Down syndrome) (q), where for the latter parameter we consider specifications in which q is assumed to be age-invariant and to vary with age as in Figure 1 .
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The results of this exploration of our model are displayed in Figures 8 through 12 .
Consider first the role that discounting plays in affecting the dynamic pattern of *  , and, thus, the incidence of amniocenteses. Figure 8 displays how *  varies with age assuming that the rate of genetic disorders associated with births is age-invariant (i.e., q a = q for all a) and there are zero (utility) costs of abortions and miscarriages (i.e.,  =  = 0). Consider first the values for *  when  = 0.0, i.e., the "myopic" model. In our characterization of the myopic model, a woman is assumed to not take account of the possibility of "replacing" a current pregnancy with a future pregnancy in her decision to get amniocentesis because she completely ignores the future.
However, we do assume that a woman takes account of the "durable" nature of children and of abortion and miscarriage costs in making her childbearing, amniocentesis and abortion decisions, via the "payoff values" D  ,  and . That is, we assume that women still take account of the PDU she receives from her child and the PDU associated with any abortion or miscarriage she experiences.
Figure 8 here
As can be seen in Figure 8 , the value for *  at early ages increases-and thus the 15 An annual rate of pregnancy of 0.3 is consistent with data from the Hutterites. The average number of births to fecund women in this population is approximately 11. In our simulations, we use this age-invariant rate, despite clear evidence that pregnancy rates tend to fall over time (see, for example, Leridon, 2008) . Allowing for a monotonically declining pregnancy rate with maternal age would tend to exacerbate the life-cycle effect, i.e. as women approach menopause without having reached the desired family size, the disutility from an amniocentesisinduced miscarriage would be greater as the probability of becoming pregnant again would be declining over time. In Figure 9 , the only change in the specifications of either the Dynamic or Myopic models is to allow the probability of a genetic disorder to vary with age, following the pattern in reflects a age-by-age response to the increasing risk of a birth defect with age; as the risk of a birth defect goes up, the incentives to learn about the potential problems with a fetus rise. With respect to the Dynamic models, the consequences of rising rates of birth defects for the age pattern in *  depend on the extent of discounting. At the extreme, if women do not discount the future at all, i.e.,  = 1.00, the likelihood of an amniocentesis does not rise with age. Rather, the option value effect noted above dominates her (their) amniocentesis decisions, giving rise to high rates of amniocentesis at early ages, while the risks of miscarriage associated with an amniocentesis, causes their utilization to decline as the woman (couple) reaches the end of the childbearing period.
Figure 9 here
In Figures 10 and 11 , we examine how the predictions of our Myopic and Dynamic models, respectively, are affected by changes in the utility costs of abortions and costs. As can be seen from these figures, higher costs to either abortion reduces the critical value for amniocenteses equally at all ages while higher costs for miscarriages tend to reduce the incidence of amniocenteses more at younger ages than at older ones. Finally, in Figure 12 , we summarize our findings by graphing the life cycle pattern of *  for both our Dynamic and Myopic models, for both age-invariant and age-varying rates of genetic disorders (1-q). While more work needs to be done in "calibrating" the Dynamic models, 16 this figure suggests that a Dynamic model in which there is some, but not complete, discounting of the future and which incorporates the age-varying rates of birth defects (1-q) displayed in Figure 1 can generate the qualitative features of the observed age-patterns in the incidence of amniocenteses. In particular, such a model is able to generate both the rise in the incidence of amniocentesis with age and the decline in its utilization at older ages. In contrast, the Myopic model we calibrate does not generate a decline in * T s   -and, thus, in the incidence of amniocenteses -as women approach menopause. 
Concluding Observations
In this paper, we examine the appropriateness of the threshold-age approach in the protocol for recommending amniocentesis testing to pregnant women, based on a dynamic model of the decision making process. In particular, we consider the potentially welfare enhancing effect of fully informing women of the risks and benefits of such a procedure, irrespective of age.
Based on our calibration exercise, it does appear that the features of our model may be important in accounting for the observed life cycle pattern of amniocenteses. In particular, the dynamic model of optimal amniocentesis choice outlined above, when it includes some, but not total, discounting of the future and conditions on increasing rates of genetic disorders with age, does appear to generate age-patterns consistent with the data. Moreover, it appears that Myopic models fail to predict the decline in the incidence of amniocentesis with age that are found in the data. While further exploration of the calibration of the Dynamic model is needed (for instance, to account for endogenous desired family size or an age-dependent pregnancy rate) these initial findings suggest real merit to develop and estimate a dynamic structural model of amniocentesis choice of the sort outlined in this paper.
These initial findings, if they hold up to further scrutiny, have potentially important implications for medical practice and insurance company policies for the funding of this procedure. In particular, our results suggest that the medical community and insurance companies may be ignoring the option value of amniocenteses when women are young.
Currently, 80% of Down syndrome children are born to women under the age of 35. Our model suggests that some of these young women, if informed of the full costs and benefits of the procedure and given the option to have it, would undergo an amniocentesis and, upon learning of the results of this test, would choose to abort a chromosomally abnormal fetus in favor of a future pregnancy that could result in a healthy birth. As such, existing guidelines of health care providers and insurance companies in setting policies for the ages at which amniocenteses will be funded are potentially inconsistent with the choices some women would make for themselves if free to acquire the information provided by this procedure. Further exploration and estimation of this model may help to inform medical practice and policy by explicitly accounting for choice behavior among women (couples) that take account of the future consequences of their actions. Hook (1981); and Hook, Cross & Schreinemachers (1983) 
